Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Head and Neck Squamous Cell Carcinoma

292 clinical trials

341 products

33 drugs

3 abstracts

Product
HS-20093
Clinical trial
ARTEMIS-006: A Phase 2 Study to Evaluate Efficacy and Safety of Intravenous Administration of HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-12
Clinical trial
A Phase 1, First-in-Human, Open-Label, Multi-Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LB-LR1109 for the Treatment of Advanced or Metastatic Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2025-11-01
Product
LB-LR1109
Clinical trial
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1 Monotherapy, SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy (BL-B01D1+SI-B003) in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Non-nasopharyngeal Carcinoma) and Other Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-01
Product
BL-B01D1
Product
SI-B003
Clinical trial
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Status: Terminated, Estimated PCD: 2023-12-01
Clinical trial
A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010).
Status: Active (not recruiting), Estimated PCD: 2023-05-30
Product
Lenvatinib
Product
Zanzalintinib
Product
Pembrolizumab
Product
NEXI-003
Clinical trial
A Phase 2 Study of ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Cisplatin + Carboplatin
Product
evorpacept
Product
pembrolizumab
Clinical trial
A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
A Safety and Efficacy Study of Intratumoral Diffusing Alpha Radiation Emitters in Recurrent Unresectable or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2026-12-01
Product
INBRX-106
Clinical trial
Phase 2/3, Randomized Study of OX40 Agonist INBRX-106 With Pembrolizumab vs Pembrolizumab as First Line Treatment for Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1(CPS ≥20)
Status: Not yet recruiting, Estimated PCD: 2029-05-01
Product
BCA101
Clinical trial
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Placebo
Clinical trial
A Phase 1a/1b Dose-escalation Study of Intravenously Administered SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-03-01
Product
SB 11285
Product
Atezolizumab
Clinical trial
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-8371 in Patients With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2025-10-01
Product
CHS-114
Clinical trial
A Phase 1 Study of CHS-114 in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-02-01
Product
CTX-8371
Clinical trial
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Terminated, Estimated PCD: 2022-07-29
Product
toripaliamab
Product
[225Ac]-FPI-1434
Clinical trial
A Phase 2, Open-label, Multicenter Study Investigating Oncolytic Immunotherapy in Combination With Other Therapy in Patients With Locoregionally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Withdrawn, Estimated PCD: 2026-03-01
Product
nivolumab
Product
RP3
Clinical trial
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas
Status: Recruiting, Estimated PCD: 2026-04-30
Product
Fludarabine
Product
ONM-501
Product
Cemiplimab
Product
89Zr-DFO-girentuximab
Clinical trial
A Phase 1 Open-Label Dose-Escalation Study of the Safety of Adoptively Transferred Autologous CD8+ T Lymphocytes Targeting HPV-16 E6/E7, HPV-18 E6/E7 and Survivin in Patients With Relapsed or Refractory HPV-related Oropharyngeal Cancers
Status: Not yet recruiting, Estimated PCD: 2026-07-01
Product
Enoblituzumab
Product
Retifanlimab
Product
Tebotelimab
Product
FPI-1175
Clinical trial
Study of 89Zr-girentuximab for PET Imaging of Solid Tumors Likely to Express High Levels of CAIX
Status: Recruiting, Estimated PCD: 2025-12-08
Product
Cyclophosphamide
Clinical trial
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
FPI-1547
Clinical trial
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
PRT3645
Product
SEA-TGT
Product
sasanlimab
Product
Brentuximab vedotin
Product
ASP-1929
Clinical trial
A Phase 1b Dose Escalation and Expansion Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination With Other Anticancer Agents in Adults With Advanced Solid Malignancies
Status: Terminated, Estimated PCD: 2023-11-01
Product
HER3 Monoclonal antibodies
Clinical trial
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SIBP-03 Injection Combined With Cetuximab in Patients With Recurrent/Metastatic Advanced Head and Neck Squamous Cell Carcinoma (Non-nasopharyngeal Carcinoma)
Status: Not yet recruiting, Estimated PCD: 2025-05-30
Product
Pegylated liposomal doxorubicin
Product
Fludarabine + Cyclophosphamide
Product
HRYZ-T101 TCR-T Cell
Product
Cetuximab
Clinical trial
Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-01
Product
ATRC-101
Product
MCLA-158
Product
NM21-1480
Clinical trial
A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2024-02-06
Clinical trial
A Phase I Study to Evaluate the Safety, Tolerance and Efficacy of HRYZ-T101 TCR-T Cell for HPV18 Positive Advanced Solid Tumor
Status: Recruiting, Estimated PCD: 2025-02-01
Product
HRYZ-T101
Clinical trial
A Phase 2 Study of ALX148 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)
Status: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Oncogene Amplifications
Status: Recruiting, Estimated PCD: 2026-09-30
Product
Ficlatuzumab
Clinical trial
A Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Status: Terminated, Estimated PCD: 2024-01-15
Product
TNO155
Product
Spartalizumab
Product
Ribociclib
Product
BBI-355
Product
NC318
Clinical trial
A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-01
Product
STK-012
Clinical trial
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Status: Completed, Estimated PCD: 2023-04-11
Product
[225Ac]-FPI-1434 Injection
Product
PBA-0405
Clinical trial
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Paclitaxel
Product
SI-B001
Product
Erlotinib
Product
Futibatinib
Product
Brentuximab Vedotin
Clinical trial
Phase 1B, Open-Label, Dose Escalation and Cohort Expansions Trial of Naptumomab Estafenatox (NAP, ABR-217620) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2026-10-01
Product
Naptumomab estafenatox
Product
Obinutuzumab
Clinical trial
An Open Label Trial of BI 765063 in Combination With BI 754091 (Ezabenlimab) Alone or With BI 836880, Chemotherapy, or Cetuximab, in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) or Hepatocellular Carcinoma (HCC)
Status: Active (not recruiting), Estimated PCD: 2024-11-29
Product
BI 836880
Clinical trial
A Phase 2 Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
Status: Recruiting, Estimated PCD: 2024-12-31
Product
VLS-1488
Clinical trial
A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects With Advanced Cancer
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 1b, Open-Label, Single-Arm Dose-Expansion Study of IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, in Combination With Nivolumab in Patients With Primary PD-1 Inhibitor Resistant Metastatic or Locally Incurable, Recurrent HNSCC
Status: Withdrawn, Estimated PCD: 2023-04-01
Clinical trial
A Multicenter, Single Arm, Open Label, Phase I Clinical Study to Evaluate the Safety, Tolerability and Efficacy of HRYZ-T101 Injection for HPV18 Positive Solid Tumor
Status: Recruiting, Estimated PCD: 2027-12-01
Product
IK-175 + Nivolumab
Product
BI 765063
Product
Ezabenlimab
Clinical trial
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (Also Known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer
Status: Recruiting, Estimated PCD: 2025-09-27
Product
TAK-186
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/ LY3650150 in Adult Participants With Perennial Allergic Rhinitis
Status: Not yet recruiting, Estimated PCD: 2025-05-30
Product
Bapotulimab
Product
Bapotulimab + Pembrolizumab
Product
BNT113
Clinical trial
An Open Label Phase II Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (AHEAD-MERIT)
Status: Recruiting, Estimated PCD: 2028-05-01
Product
TBio-4101
Clinical trial
A Phase 1b Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (STARLING)
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Vobramitamab Duocarmazine
Clinical trial
A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2027-05-01
Product
Vobramitamab
Product
volrustomig
Clinical trial
A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)
Status: Recruiting, Estimated PCD: 2029-01-19
Product
NRC-2694-A
Product
INBRX-105
Clinical trial
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 / 2 Study of INBRX-105 and INBRX-105 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase 1, First-in-human, Multicentre, Open-label, Dose Escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
Status: Recruiting, Estimated PCD: 2026-12-30
Product
FPI-2053
Product
[111In]-FPI-2107
Product
[225Ac]-FPI-2068
Clinical trial
A Phase 1/2, Open-label, Dose-escalation, and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Therapeutic Activity of GI-101 as a Single Agent and in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Patients With Advanced or Metastatic Solid Tumors (Keynote B59)
Status: Recruiting, Estimated PCD: 2025-10-01
Product
Naptumomab estafenatox and Durvalumab
Product
GI-101
Product
GI-101A
Clinical trial
Phase I/II First-in-Human Study of TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-05-14
Product
TT-10
Clinical trial
A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-08-11
Product
TAK-500
Clinical trial
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Recruiting, Estimated PCD: 2024-04-01
Product
HFB301001
Clinical trial
A Dose Escalation Study of HFB301001 (OX40 Agonist Antibody) in Adult Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
SO-C101
Clinical trial
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY OF PF-07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Status: Terminated, Estimated PCD: 2023-10-16
Product
HFB200301
Product
Tislelizumab
Clinical trial
A Phase I Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and IL-2 Coding Oncolytic Adenovirus TILT-123 and Avelumab in Solid Tumor Patients (Melanoma and SCCHN) Refractory to or Progressing After Anti-PD(L)1
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-01
Product
PF-07265028
Product
Sasanlimab
Product
TILT-123
Product
Avelumab
Product
TJ107
Clinical trial
A Multicenter, Open-label, Exploratory Phase II Clinical Study to Evaluate the Safety and Tolerability and Preliminary Efficacy of TJ107 Combine With Pembrolizumab Injection in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2025-03-31
Product
FID007
Clinical trial
A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010).
Status: Active (not recruiting), Estimated PCD: 2023-08-25
Clinical trial
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
Status: Terminated, Estimated PCD: 2023-11-28
Product
Ladiratuzumab vedotin
Product
TransCon TLR7/8 Agonist
Clinical trial
Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Product
Docetaxel
Product
Cisplatin
Product
Zimberelimab
Product
Magrolimab
Product
5-FU
Product
Carboplatin
Clinical trial
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-02-01
Product
ABBV-514
Product
Budigalimab
Product
XL092
Product
Nivolumab
Clinical trial
A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With ABBV-514 as a Single Agent and in Combination With Budigalimab
Status: Recruiting, Estimated PCD: 2026-05-04
Product
Ipilimumab
Product
Nivolumab + Relatlimab
Clinical trial
A Phase I-II, First-in-Human Study of SKB264 in Patients With Locally Advanced Unresectable /Metastatic Solid Tumors Who Are Refractory to Available Standard Therapies
Status: Recruiting, Estimated PCD: 2024-11-01
Product
ONM-100
Product
RC198
Clinical trial
Phase I Study of TTI-101, an Oral Inhibitor of Signal Transducer and Activator of Transcription (STAT) 3, in Patients With Advanced Cancers
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
TTI-101
Clinical trial
A Phase 1b/2a, Open-Label, Multi-Center Study of CyPep-1 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety of CyPep-1 in Patients With Advanced or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC), Melanoma, or Triple-Negative Breast Cancer (TNBC) (CATALYST)
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Product
CyPep-1
Clinical trial
International, Multicenter, Double-blind, Randomized, Comparative Study of the Pharmacokinetics, Safety and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms
Status: Active (not recruiting), Estimated PCD: 2023-12-11
Product
RPH-075
Clinical trial
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-01
Product
GEN1042
Product
Gemcitabine
Product
Pemetrexed
Product
Nab paclitaxel
Clinical trial
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance, Safety & Timing of Postdose Imaging of ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Solid Tumors Undergoing Routine Surgery
Status: Completed, Estimated PCD: 2021-10-14
Product
SCB01A
Clinical trial
An Open-Label, Phase II Study to Evaluate SCB01A in Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer Who Have Received Platinum-Based Treatment
Status: Terminated, Estimated PCD: 2017-12-01
Clinical trial
A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination With IV Pembrolizumab vs IV Pembrolizumab Monotherapy
Status: Completed, Estimated PCD: 2022-09-30
Clinical trial
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Status: Terminated, Estimated PCD: 2020-09-16
Product
JAB-3312
Product
RPTR-168
Product
ADCT-301
Clinical trial
A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2023-12-01
Product
MIT-001
Product
RM-1995
Clinical trial
A Phase 1 First-in-Human, Drug-dose Escalation Study of RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced Cutaneous Squamous Cell Carcinoma or With Head and Neck Squamous Cell Carcinoma
Status: Withdrawn, Estimated PCD: 2023-01-30
Clinical trial
A Multi-Cohort Exploratory Study of Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC
Status: Recruiting, Estimated PCD: 2025-04-22
Product
fianlimab
Clinical trial
A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 Monotherapy or in Combination With Cetuximab as a Salvage Regimen for Solid Tumors
Status: Completed, Estimated PCD: 2023-03-30
Product
cemiplimab
Product
CDX-3379
Clinical trial
Phase 2, Open-Label, Multicenter Study of INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Withdrawn, Estimated PCD: 2024-04-20
Product
retifanlimab
Clinical trial
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of RPTR-168 in Patients With Relapsed/Refractory HPV-16 E6/E7 Positive Tumors and Melanoma
Status: Terminated, Estimated PCD: 2022-09-14
Clinical trial
A Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Immunogenetic and Efficacy of RC198 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-30
Product
NBTXR3
Product
INCAGN01876
Clinical trial
Phase 1/2 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors
Status: Recruiting, Estimated PCD: 2024-10-15
Clinical trial
A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC
Status: Recruiting, Estimated PCD: 2024-07-01
Product
NGM120
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of MIT-001 in Prevention of Oral Mucositis in Patients Receiving CCRT for Locally Advanced HNSCC
Status: Recruiting, Estimated PCD: 2024-04-30
Product
NEO-201
Product
Ulevostinag
Product
Platinum Doublet
Clinical trial
A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2022-12-08
Product
IO102-IO103
Clinical trial
A Phase II Multi-Arm (Basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination With Pembrolizumab, as First-Line Treatment for Patients With Metastatic NSCLC, SCCHN, or Metastatic mUBC
Status: Recruiting, Estimated PCD: 2024-04-30
Product
NKTR-255
Product
AP203
Clinical trial
A Phase 1/2, Open-label Study of the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination With Capecitabine, Given Orally on a Daily Schedule in Patients With Advanced Solid Tumors or Lymphoma
Status: Active (not recruiting), Estimated PCD: 2023-05-01
Product
SKB264
Product
GZ17-6.02
Product
Capecitabine
Clinical trial
A Phase 1/2 Study of RTX-224 for the Treatment of Patients With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2022-11-30
Product
TAK-676
Product
TAK-676 + Carboplatin
Clinical trial
TAK-676 Alone and in Combination(s) With Carboplatin, 5-Fluorouracil, and Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma
Status: Completed, Estimated PCD: 2022-11-15
Product
Tavokinogene Telseplasmid
Clinical trial
A Multicenter Phase II Trial of Intratumoral pIL-12 Electroporation in Treatment-Refractory Metastatic and Unresectable SCC of the Head and Neck
Status: Terminated, Estimated PCD: 2016-11-14
Product
Carboplatin + Paclitaxel
Product
Carboplatin + 5-FU
Product
TAK-676 + Carboplatin + 5-FU
Product
TAK-676 + Carboplatin + Paclitaxel
Product
CAN04
Clinical trial
An Open-label, Safety and Tolerability Phase 1b Trial of CAN04, a Fully Humanized Anti-IL1RAP Monoclonal Antibody, and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Status: Completed, Estimated PCD: 2023-06-28
Clinical trial
Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study
Status: Recruiting, Estimated PCD: 2024-12-31
Product
AI-061
Clinical trial
An Open-label, Multi-center, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors.
Status: Completed, Estimated PCD: 2022-10-13
Product
RTX-224
Product
Copanlisib
Clinical trial
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) With or Without Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies
Status: Terminated, Estimated PCD: 2022-05-09
Product
NKTR-262
Clinical trial
Evaluate the Efficacy and Safety of HLX10, PD-1 mAb, in Combination With HLX07, EGFR mAb, in Patients With Advanced Head And Neck Tumors
Status: Active (not recruiting), Estimated PCD: 2024-05-30
Product
HLX07
Product
Cisplatin/Carboplatin
Product
HLX10
Product
bempegaldesleukin
Clinical trial
Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Product
N-803
Product
N-803 + Pembrolizumab + PD-L1 t-haNK
Product
MCLA-129
Product
Osimertinib
Product
N-803 + Pembrolizumab
Product
N-803 + Nivolumab
Product
N-803 + Atezolizumab
Product
N-803 + Avelumab
Product
OR2805
Clinical trial
A Phase 1-2 Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents in Subjects With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2024-04-15
Clinical trial
A Phase 1b/2 Study of Duvelisib in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Status: Terminated, Estimated PCD: 2020-12-10
Product
Duvelisib
Product
[225Ac]-FPI-1966
Product
[111In]-FPI-1967
Product
vofatamab
Clinical trial
A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours
Status: Terminated, Estimated PCD: 2023-09-08
Product
[Ga-68]-PNT6555
Product
[Lu-177]-PNT6555
Clinical trial
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
Abraxane
Drug
Cisplatin
Clinical trial
HNSALV Trial: Combining Immunotherapy With Salvage Surgery and IORT for Treatment of Persistent/Recurrent Head and Neck Cancers
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase I Trial of Re-Irradiation With Concurrent Chemotherapy in Combination With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2026-01-01
Drug
Pamiparib
Drug
hydroxyurea
Clinical trial
Phase II Basket Trial Evaluating the Efficacy of a Combination of Pembrolizumab and Vorinostat in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2022-12-15
Product
Fluorouracil
Clinical trial
A Phase IIa Trial of sEphB4-HSA in Combination With Anti PD-1 Antibody (Pembrolizumab, MK3475) in Patients With Non-small Cell Lung and Head/Neck Cancer
Status: Active (not recruiting), Estimated PCD: 2025-03-10
Product
Recombinant EphB4-HSA Fusion Protein
Clinical trial
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Recruiting, Estimated PCD: 2025-07-31
Product
Peposertib
Clinical trial
A Pilot Study of Neoadjuvant Cemiplimab With Platinum-Doublet Chemotherapy, and Cetuximab in Patients With Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2026-06-20
Drug
AN0025
Drug
Docetaxel
Clinical trial
A Phase 2 Trial of PD-L1 t-haNK, N-803 IL-15 Superagonist (Anktiva), and Cetuximab for Immunotherapy-treated Patients With Recurrent, Metastatic HNSCC (QUILT-505)
Status: Recruiting, Estimated PCD: 2025-07-31
Product
PD-L1 t-haNK
Drug
N-803
Clinical trial
A Pilot Study of Radiation De-Escalation for p16 Negative Oropharyngeal Cancer and p16-Negative or Positive Laryngeal and Hypopharyngeal Cancers
Status: Recruiting, Estimated PCD: 2027-03-12
Product
Tolinapant
Clinical trial
Randomized Trial Comparing Low-Dose Weekly to High-Dose Cisplatin Concurrent With Radiation for Locally Advanced Head and Neck Cancer.
Status: Recruiting, Estimated PCD: 2028-09-01
Product
High-Dose Cisplatin
Clinical trial
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers: Phase 2 Randomized Trial (VALUE-CHECK)
Status: Not yet recruiting, Estimated PCD: 2029-03-30
Product
Standard of Care
Clinical trial
A Phase II Study of Efficacy and Safety of Induction Modified TPF (mTPF) Followed by Concurrent Chemoradiotherapy (CCRT) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)
Status: Recruiting, Estimated PCD: 2024-05-01
Product
TPF
Clinical trial
Comparison of Concomitant Cisplatin Versus Carboplatin and 5-fluorouracil With Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Status: Completed, Estimated PCD: 2017-03-01
Product
cisplatin
Drug
carboplatin
Drug
5-FU
Clinical trial
Preoperative Immune Checkpoint Inhibitor Therapy for Patients With Primary Untreated or Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN)
Status: Completed, Estimated PCD: 2023-10-17
Clinical trial
A Lithium-containing Mouthwash Prevention and Treatment of Oral Mucositis and Dysgeusia in Patients Undergoing Radiotherapy
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Product
Lithium-containing mouthwash
Product
Placebo mouthwash
Product
Lithium-containing Mouthwash
Clinical trial
Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Cancer Patients Undergoing Surgery
Status: Recruiting, Estimated PCD: 2024-08-01
Product
HuMax-IL8
Clinical trial
Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Not yet recruiting, Estimated PCD: 2025-11-30
Clinical trial
In Situ Vaccination With Flt3L, Radiation, and Poly-ICLC Combined With Pembrolizumab in Patients With Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, and Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2025-03-01
Product
Flt3L
Product
Poly ICLC
Clinical trial
MITRIC: Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clincal Responders
Status: Recruiting, Estimated PCD: 2034-03-31
Product
Fecal Microbiota Transplant
Clinical trial
Open-Label, Randomized Phase 2 Trial of Ramucirumab in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-Line Treatment of PD-L1 Positive, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma (RM-HNSCC)
Status: Recruiting, Estimated PCD: 2028-04-30
Product
Ramucirumab
Clinical trial
A Phase Ib/II Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab in Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2027-11-21
Product
Phase Ib ARRY-614 + nivolumab
Product
ARRY-614 + Nivolumab + Ipilimumab
Product
Phase II ARRY-614 + Nivolumab
Product
Phase II ARRY-614 + Nivolumab + Ipilimumab
Product
Phase II ARRY-614 + Nivolumab + Ipilimumab (RCC)
Clinical trial
A Phase I/II Study Evaluating the Safety and Clinical Activity of Anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) Antibodies Administrated in Combination With Stereotactic Body Radiotherapy (SBRT) in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck, Lung, Oesophageus, Cervix, Vagina,Vulva or Anus
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Product
Durvalumab
Clinical trial
A Phase II Multi-Centre Study Evaluating the Efficacy of Dacomitinib for Patients With Epidermal Growth Factor Receptor (EGFR)-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expression or Other Novel Emerging Biomarkers
Status: Recruiting, Estimated PCD: 2025-07-01
Product
Dacomitinib
Clinical trial
A Phase 1 Trial of CTLA-4 Inhibition, With or Without Cetuximab, and in Combination With Memory-like Natural Killer (NK) Cell Immune Cell Therapy in Advanced Head & Neck Cancer
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Interleukin-15 Superagonist
Product
CIML NK cell Infusion
Clinical trial
Safety and Efficacy of Pembrolizumab in Combination With Low-dose PF (Cisplatin and 5-Fluorouracil) as Neoadjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma: a Multi-center, Single-arm Clinical Study Trial
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Pembrolizumab + Cisplatin + 5-FU
Product
Tremelimumab
Clinical trial
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-09-30
Product
VET3-TGI
Clinical trial
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)
Status: Recruiting, Estimated PCD: 2025-02-24
Product
Neoantigen Peptide Vaccine
Product
Bevacizumab
Clinical trial
Phase Ib/II Non-randomized Non-comparative Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2027-09-01
Product
Dostarlimab
Product
Niraparib
Product
Cisplatin + Radiotherapy
Clinical trial
A Phase II Study of Sorafenib in Combination With Carboplatin and Paclitaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Drug
Tiragolumab
Product
Sorafenib
Clinical trial
A Phase I/II Basket Trial of the EGF Vaccine CIMAvax in Combination With Anti-PD1 Therapy in Patients With Advanced NSCLC or Squamous Head and Neck Cancer
Status: Recruiting, Estimated PCD: 2027-12-09
Product
Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Clinical trial
A Prospective Study of Pembrolizumab Combined With Chemotherapy (Cisplatin or Carboplatin + Albumin-bound Paclitaxel) in First-line Therapy for Patients With Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Completed, Estimated PCD: 2023-08-20
Clinical trial
Pilot Phase II Study to Evaluate Effect of Cetuximab Given as Single Agent After Immunotherapy With PD-1 Inhibitors in Patients With Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Neoadjuvant Pembrolizumab and IO102-103 Prior to Curative-intent Surgical Care for Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status: Recruiting, Estimated PCD: 2026-10-16
Product
IO102-103
Clinical trial
A Non-randomized Phase II Study of Apatinib and Tegafur Gimeracil Oteracil Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck
Status: Completed, Estimated PCD: 2020-09-30
Product
Apatinib Mesylate
Product
Tegafur Gimeracil Oteracil Potassium
Clinical trial
A Single Arm Phase I/II Study of MK-3475 Combined With Vorinostat for Recurrent Unresectable and/or Metastatic Squamous Cell Head and Neck Cancer and Recurrent Unresectable and/or Metastatic Salivary Gland Malignancies
Status: Completed, Estimated PCD: 2019-09-28
Product
Vorinostat
Clinical trial
A Phase I/II Study of Concurrent Cetuximab and Nivolumab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2021-09-04
Clinical trial
First-line Treatment of Locally Advanced HNSCC With Double Checkpoint Blockade and Radiotherapy Dependent on Intratumoral CD8+ T Cell Infiltration (CheckRad-CD8, EudraCT NUMBER: 2017-003226-33)
Status: Completed, Estimated PCD: 2021-09-16
Product
Durvalumab + Tremelimumab + RT
Clinical trial
Real-time Margin Assessment in Head and Neck Cancer - Enhancing Specificity by Combining Fresh Frozen Sectioning With Targeted Fluorescence Imaging
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Cetuximab-IRDye800
Clinical trial
A Pilot Study of 18F-FDG PET-CT Kinetic Analysis in Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Recruiting, Estimated PCD: 2028-11-01
Product
18-F FDG
Clinical trial
Radiotherapy Plus Xevinapant or Placebo in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma: a Randomized Phase II Study RAVINA
Status: Recruiting, Estimated PCD: 2029-07-01
Product
Xevinapant
Clinical trial
A Phase I Study of Avelumab, Palbociclib, and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2020-02-04
Product
Palbociclib
Clinical trial
Phase 1 Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase II Clinical Trial To Evaluate the Efficacy and Safety of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Non-nasopharyngeal Carcinoma) and Other Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Drug
PD-1 monoclonal antibody
Clinical trial
Phase 1 Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors
Status: Recruiting, Estimated PCD: 2024-10-01
Product
IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
Clinical trial
A Single-arm，Single Center，Prospective，Phase II Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy for Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Camrelizumab
Product
Lobaplatin
Clinical trial
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)
Status: Recruiting, Estimated PCD: 2027-01-11
Clinical trial
Neoadjuvant Adebrelimab Plus Dalpiciclib in HPV-negative Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial
Status: Not yet recruiting, Estimated PCD: 2026-12-31
Product
Adebrelimab + Dalpiciclib
Clinical trial
Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherapy for Head and Neck Tumor: A Randomized, Placebo-Controlled, Double-Blind Trial
Status: Completed, Estimated PCD: 2022-11-30
Product
Streptococcus salivarius K12
Clinical trial
A Pilot Trial of Electronic Cigarettes in Patients Diagnosed With Cancers of the Head, Neck, and Lung
Status: Withdrawn, Estimated PCD: 2024-01-31
Product
Nicotine Replacement
Clinical trial
A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking Antibodies
Status: Completed, Estimated PCD: 2022-10-20
Product
Enzyme Inhibitor
Clinical trial
Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients: A Pilot Study
Status: Active (not recruiting), Estimated PCD: 2024-04-04
Product
Buprenorphine
Product
Tramadol
Drug
mFOLFOX6
Product
N-803 + Nivolumab + PD-L1 t-haNK
Product
N-803 + Atezolizumab + PD-L1 t-haNK
Product
N-803 + Avelumab + PD-L1 t-haNK
Product
N-803 + Durvalumab + PD-L1 t-haNK
Clinical trial
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Quad-Shot Radiotherapy in Combination With Immune Checkpoint Inhibition for Advanced/Recurrent Head and Neck Cancer
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-04-01
Product
P-MUC1C-ALLO1 CAR-T cells
Product
Rimiducid
Clinical trial
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-08-26
Product
LY4101174
Clinical trial
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Terminated, Estimated PCD: 2023-11-15
Product
Birinapant
Clinical trial
Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2 (ROMA LA-OPSCC-2)
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
MET-4
Clinical trial
A Phase Ib/II Multicenter Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
Status: Not yet recruiting, Estimated PCD: 2025-07-01
Drug
pembrolizumab
Product
valemetostat
Clinical trial
Neoadjuvant/Phase 1 Study of CD40 Agonist (LVGN7409) and PD-1 Inhibitor (LVGN3616) in Patients With Resectable HPV-negative Head/Neck Squamous Cell Carcinoma (HNSCC)
Status: Not yet recruiting, Estimated PCD: 2028-03-01
Product
LVGN 3616
Product
CD 40 Agonist - LVGN 7409
Clinical trial
Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Phase 1-2 Trial
Status: Terminated, Estimated PCD: 2022-08-09
Product
Tazemetostat
Clinical trial
Phase Ib Study of Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy (SBRT) in Patients With Locoregionally Recurrent, Refractory, or Oligometastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Recruiting, Estimated PCD: 2026-12-01
Drug
Losartan
Clinical trial
A Window of Opportunity Trial of NT-I7 in Patients With Locally Recurrent Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Salvage Surgery
Status: Recruiting, Estimated PCD: 2025-03-31
Product
Efineptakin alfa
Clinical trial
Early-Phase Open-label Study of Tolinapant and Radiation in Cisplatin-Ineligible Patients With Previously Untreated, Locally Advanced Head and Neck Cancer
Status: Recruiting, Estimated PCD: 2025-10-21
Clinical trial
Neoadjuvant Tislelizumab (BGB-A317, Anti-PD-1 Antibody) Plus Nab-Paclitaxel and Carboplatin for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma : A Single-arm, Phase II Trial
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Extended Dosing Interval
Clinical trial
A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-30
Product
CAdVEC
Clinical trial
Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study
Status: Recruiting, Estimated PCD: 2024-09-01
Product
Cabozantinib
Drug
cyclophosphamide
Clinical trial
Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2029-03-25
Product
Tislelizumab（neoadjuvant）
Product
Nab-paclitaxel
Product
Cisplatin（adjuvant）
Product
Tislelizumab（adjuvant）
Product
Carboplatin（neoadjuvant）
Product
Carboplatin（adjuvant）
Clinical trial
The Safety and Feasibility of Neoadjuvant Camrelizumab With Dalpiciclib for the Treatment of Resectable Esophageal or Head and Neck Squamous Cell Carcinoma：A Phase 1 Trial
Status: Recruiting, Estimated PCD: 2024-10-31
Product
Dalpiciclib
Clinical trial
Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.
Status: Recruiting, Estimated PCD: 2024-06-30
Product
Methylnaltrexone
Clinical trial
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor: A Multicenter, Open-Label, Randomized Phase 3 Trial
Status: Recruiting, Estimated PCD: 2027-02-28
Clinical trial
A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head And Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood
Status: Recruiting, Estimated PCD: 2025-01-25
Drug
PD-1 antibody
Clinical trial
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Single-Arm, Phase 2 Trial
Status: Active (not recruiting), Estimated PCD: 2025-11-30
Product
Olaparib
Clinical trial
A Phase II Study of Pembrolizumab for Patients With Head and Neck Squamous Cell Carcinoma With Residual Disease Following Definitive Chemoradiation
Status: Terminated, Estimated PCD: 2020-02-01
Clinical trial
Pembrolizumab Alone and in Combination(s) With MK-0482 and MK-4830 Via Intratumoral Injection in Patients With Head and Neck Squamous Cell Carcinoma or Soft Tissue Sarcoma Prior to Planned Surgical Intervention
Status: Completed, Estimated PCD: 2023-06-22
Product
MK-0482 + Pembrolizumab
Product
MK-4830 + Pembrolizumab
Clinical trial
A Phase II Clinical Study of Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2024-12-30
Product
Penpulimab
Product
albumin-paclitaxel
Clinical trial
Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for the Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Trial (neoCHANCE-2 Trial)
Status: Recruiting, Estimated PCD: 2023-08-19
Product
Afatinib
Clinical trial
A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2027-01-01
Product
BGB-A425
Drug
LBL-007
Clinical trial
A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-05-29
Clinical trial
Pharmacodynamic Effects and Predictive Biomarkers of Janus Kinases (JAK)/Signal Transducer and Activator of Transcription (STAT) Inhibition With Ruxolitinib in Operable Head and Neck Cancer: a Window Trial
Status: Completed, Estimated PCD: 2023-10-18
Product
Ruxolitinib
Clinical trial
A Phase II Neoadjuvant Study of the Safety and Tolerability of Anti-PD1 (Nivolumab) Administered Alone or in Combination With Anti-LAG3 (Relatlimab) or Anti-CTLA4 (Ipilimumab) in Resectable Head and Neck Cancer
Status: Recruiting, Estimated PCD: 2027-05-31
Product
Relatlimab
Clinical trial
Postoperative Concurrent Chemoradiotherapy Followed by Anti-PD-1 Antibody Maintenance Therapy in High-Risk Locally Advanced Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2025-11-30
Product
Anti-PD-1 monoclonal antibody
Clinical trial
Toripalimab Maintenance After First-line Comprehensive Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: a Single-arm, Phase II Study
Status: Not yet recruiting, Estimated PCD: 2026-02-01
Clinical trial
Feasibility of the Enhanced Tobacco Intervention Protocol (ETIP) to Reduce Smoking and Potentially Alter the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma and Non-Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-08-16
Product
Bupropion Hydrochloride
Product
Varenicline
Clinical trial
EFFECT-neo: A Prospective, Open-label, Multicenter Phase III Study to Evaluate Efficacy and Safety of Pembrolizumab Combined With Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Status: Recruiting, Estimated PCD: 2027-04-30
Drug
Nedaplatin
Product
Liposomal paclitaxel
Clinical trial
Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2025-03-31
Product
Panitumumab
Clinical trial
A Phase II Trial of the Efficacy and Safety of the Combination of Cemiplimab and Low-Dose Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase II Study of NBTXR3 Activated by Radiation and Combined With Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Limited PD-L1 Expression or Refractory to PD-1 Blockade
Status: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
A Prospective Phase I and II Trial of Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Efficacy and Safety of PD-1 Inhibitor Combined With Chemotherapy in Locally Advanced (III-IVB) Poorly Differentiated Head and Neck Squamous Cell Carcinoma: a Multi Cohort, Prospective Phase II Study
Status: Not yet recruiting, Estimated PCD: 2025-10-31
Product
Paclitaxel-albumin
Clinical trial
Phase II Trial of Tislelizumab, an Anti-PD-1 Monoclonal Antibody, in Combination With Dasatinib and Quercetin, as a Novel Neoadjuvant Pre-Surgical Therapy for Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Tislelizumab + Dasatinib + Quercetin
Clinical trial
An Open, Single-center, Phase II Trial of Cetuximab+Zimberelimab Combined With Platinum-containing Dual-agent Neoadjuvant Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Status: Not yet recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase II Randomised Controlled Study Assessing the Role of Dose Escalation Using [18F] FMISO PET CT in Head and Neck Cancer: The DE-HyART (Dose Escalation Using Hypoxia-adjusted Radiotherapy) Protocol
Status: Recruiting, Estimated PCD: 2028-04-01
Clinical trial
A Phase I/II Trial of Cetuximab in Combination With Interleukin-12 Administered to Patients With Unresectable Primary or Recurrent Squamous Cell Carcinoma of the Head and Neck
Status: Active (not recruiting), Estimated PCD: 2015-09-29
Product
Edodekin alfa
Clinical trial
A Phase 2 Feasibility Study Combining Pembrolizumab and Metformin to Harness the Natural Killer Cytotoxic Response in Metastatic Head and Neck Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Product
Metformin Extended Release
Clinical trial
A Prospective, Single-arm, Phase II Study of Adelbelimab Combined With Carboplatin and Nab-paclitaxel in Neoadjuvant Therapy for Patients With Resectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Product
Nab-Paclitaxel
Product
adelbelimumab
Clinical trial
Open-label Phase II Trial for the Combination of GX-188E HPV DNA Vaccine With GX-I7 or Pembrolizumab OR the Triple Combination of GX-188E HPV DNA Vaccine, GX-I7, and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 or 18 Positive Head and Neck Cancer (Expanded Cohort)
Status: Recruiting, Estimated PCD: 2025-08-01
Product
GX-188E
Clinical trial
A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types
Status: Recruiting, Estimated PCD: 2024-08-31
Product
NX-1607
Clinical trial
Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and Ipilimumab
Status: Recruiting, Estimated PCD: 2026-05-01
Drug
T-VEC
Clinical trial
An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects With Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation
Status: Recruiting, Estimated PCD: 2026-08-01
Product
Autologous, engineered T Cells targeting TP53 R175H
Clinical trial
Phase 1 Dose Escalation Trial of ZM008, an Anti-LLT1 Antibody, as Single Agent Followed by Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-01
Product
ZM008
Clinical trial
An Open, Single-center, Phase II Trial of Cadonilimab Combined With Platinum-containing Dual-agent Neoadjuvant Therapy for Locally Advanced Operable Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2024-12-31
Drug
AK104
Clinical trial
Window of Opportunity for Durvalumab (MEDI4736) Plus Metformin Trial of in Squamous Cell Carcinoma of the Head and Neck
Status: Completed, Estimated PCD: 2021-11-20
Drug
Metformin
Drug
Varlilumab
Clinical trial
Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-09-16
Product
BGB-A445
Drug
tislelizumab
Clinical trial
Phase II Study of IMRT Re-Irradiation With Concurrent/Adjuvant Nivolumab in Patients With Locoregionally Recurrent or Second Primary Squamous Cell Cancer of the Head and Neck
Status: Active (not recruiting), Estimated PCD: 2023-12-07
Clinical trial
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Select Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-01
Product
VV1
Clinical trial
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of Rilvegostomig, Volrustomig, and Sabestomig
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Rilvegostomig
Product
Volrustomig
Product
Sabestomig
Clinical trial
Official Title Targeted Dual Modality Imaging (TDMI) for Detection and Removal of Head and Neck Cancer
Status: Recruiting, Estimated PCD: 2027-12-31
Product
Panitumumab-IRDye800
Clinical trial
Phase II Study Evaluating HPV-16 Vaccination (ISA101b) and Pembrolizumab Plus Cisplatin Chemoradiotherapy for "Intermediate Risk" HPV-16 Associated Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Recruiting, Estimated PCD: 2027-06-30
Drug
ISA101b
Clinical trial
Study Evaluating 89Zr Panitumumab for Assessment of Indeterminate Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2027-02-28
Product
Zirconium Zr 89 Panitumumab
Clinical trial
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2025-08-01
Drug
fluorouracil
Clinical trial
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
Status: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Status: Active (not recruiting), Estimated PCD: 2022-09-20
Drug
Atezolizumab
Clinical trial
A Phase II Trial to Assess the Efficacy and Safety Profile of Pembrolizumab in Patients With Performance Status 2 With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
A Phase II Study of Pembrolizumab in Combination With Circulating Tumor DNA Response-Adaptive Pulsed Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: The SINERGY Trial (Squamous Cell Carcinoma of Head and Neck Response-Guided Therapy)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Carrilizumab Combined With Bevacizumab Plus Capecitabine in a Second-line Prospective, One-arm Exploratory Study of Relapsed Metastatic Squamous Cell Carcinoma of Head and Neck
Status: Not yet recruiting, Estimated PCD: 2025-04-01
Product
Carrilizumab
Clinical trial
Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Status: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Status: Withdrawn, Estimated PCD: 2027-07-01
Product
GR-MD-02
Clinical trial
A Phase I/II Clinical Study of JS004, a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA), in Subjects With Head and Neck Cancer
Status: Completed, Estimated PCD: 2023-03-06
Product
JS004
Product
JS001
Clinical trial
A Prospective Phase II Trial to Evaluate the Safety and Efficacy of Neoadjuvant Radiotherapy Combined With Immunotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Status: Not yet recruiting, Estimated PCD: 2024-05-20
Clinical trial
A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Approved Agents in Patients With Advanced Solid Tumours
Status: Recruiting, Estimated PCD: 2024-08-01
Product
Fosifloxuridine
Clinical trial
A Phase II, Open-Label, Single-arm Study of Toripalimab As Consolidation Therapy After Postoperative Radiotherapy or Chemoradiotherapy in Patients With Head and Neck Squamous Cell Carcinomas (HNSCC)
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Toripalimab
Clinical trial
HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy Open-label Phase 2 Clinical Trial With Lead-In Safety Cohort
Status: Recruiting, Estimated PCD: 2026-03-01
Product
nivolumab-GX-188E-GX-I7
Clinical trial
A Phase 3, Prospective，Multicenter, Randomized Open-Label Trial to Compare the Efficacy and Safety of Tislelizumab (BGB A317, Anti-PD1 Antibody) Combined With Chemotherapy Followed By Surgery Versus Up-Front Surgery as Treatment for Resectable Head And Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2028-10-01
Clinical trial
Paclitaxel Plus Cetuximab for the Treatment of Recurrent and/or Metastatic Head and Neck Cancer After First-line Checkpoint Inhibitor Failure: A Multicenter, Single Arm Study
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Phase II Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma With Evaluation of Neoadjuvant Biomarker Modulation With TARCEVA vs. TARCEVA Plus Sulindac
Status: Completed, Estimated PCD: 2014-09-01
Drug
Erlotinib
Product
Erlotinib plus sulindac
Clinical trial
Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)
Status: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
Phase 2 Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2023-06-01
Product
IPI-549
Clinical trial
The Effect of Prebiotic Inulin on Patients Affected by Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Treated With Immune Checkpoint Inhibitors (ICIs): Princess Study
Status: Recruiting, Estimated PCD: 2024-12-02
Clinical trial
Smoking Cessation in Patients With Squamous Cell Cancer of the Head and Neck Undergoing Radiation Therapy With or Without Chemotherapy
Status: Terminated, Estimated PCD: 2018-10-06
Product
Bupropion
Clinical trial
Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin-3 Inhibitor (GB1211) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2028-02-01
Product
GB1211
Clinical trial
Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck or Metastatic Breast Cancer
Status: Completed, Estimated PCD: 2019-09-18
Product
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Clinical trial
A Phase II Trial of Induction and Adjuvant Camrelizumab Combined With Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Concurrent cisplatin
Clinical trial
Single-Arm Trial of EBV-Specific TCR-T Cells With Anti-PD1 Auto-secreted Element in the Treatment of EBV-Positive Head and Neck Carcinoma
Status: Recruiting, Estimated PCD: 2024-01-01
Product
EBV-specific TCR-T cell with anti-PD1 auto-secreted element
Clinical trial
A Phase II Study of Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2026-03-01
Product
Tadalafil
Clinical trial
Combined Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC in PD-L1 Positive Patients (CPS≥1)
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®808 in Combination With Pembrolizumab in Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-12-01
Product
XmAb®808
Product
Keytruda
Clinical trial
Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Primary Mediastinal Large B-cell Lymphoma, Renal Cell Carcinoma, Small Cell Lung Cancer, Microsatellite Instability-High/Mismatch Repair Deficient Cancer, or for the Treatment of Adult Patients With Unresectable or Metastatic Tumor Mutational Burden-High Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2021-10-31
Product
L-NMMA
Clinical trial
A Phase II Trial of Pembrolizumab and Cabozantinib in Patients With RM SCCHN
Status: Active (not recruiting), Estimated PCD: 2024-01-05
Clinical trial
A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2025-03-20
Product
18F-FSPG
Product
11C-Glutamine
Clinical trial
Biomarker Driven Phase 1/1b Trial of ASTX727 and Nivolumab in Patients With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Not yet recruiting, Estimated PCD: 2025-02-28
Product
INQOVI
Clinical trial
A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2028-02-01
Product
ALE.C04
Clinical trial
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Status: Terminated, Estimated PCD: 2023-09-27
Abstract
https://www.abstractsonline.com/pp8/#!/10517/presentation/20249
Product
Pepinemab + Pembrolizumab
Clinical trial
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2026-07-01
Product
BL-B16D1
Clinical trial
Phase I/II of Durvalumab (MEDI4736) + Tremelimumab + Stereotactic Body Radiotherapy for Metastatic Head and Neck Carcinoma
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
Phase II Multicenter Randomized Trial to Assess the Efficacy and Safety of First Line Nivolumab in Combination With Paclitaxel in Subjects With R/M HNSCC Unable for Cisplatin-based Chemotherapy (NIVOTAX)
Status: Active (not recruiting), Estimated PCD: 2023-09-01
Product
Nivolumab + Paclitaxel
Product
Cetuximab + Paclitaxel
Clinical trial
A Phase 2 Study of LVGN6051 Combined With Toripalimab and Paclitaxel for Recurrent/Metastatic HNSCC Rapidly Progressed From Previous Platinum-containing Curative Treatment or Contraindicated for Platinum-containing Treatment
Status: Not yet recruiting, Estimated PCD: 2027-10-31
Product
LVGN6051 Monoclonal Antibody
Clinical trial
Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Product
Netopitam Palonosetron
Clinical trial
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
Status: Recruiting, Estimated PCD: 2027-12-31
Product
Pegsitacianine
Clinical trial
A Phase 2 Study of Preoperative Pembrolizumab and Chemotherapy Followed by Adjuvant Pembrolizumab in Resectable Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2025-05-20
Product
CISPLATIN
Drug
fludarabine
Clinical trial
Phase I Trial of BAY 1895344 ATR Inhibitor Combined With Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2024-11-27
Product
Elimusertib
Clinical trial
A Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma
Status: Completed, Estimated PCD: 2021-06-28
Clinical trial
Prospective, One-arm, Phase II Clinical Study of Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in Patients With Resectable Squamous Cell Carcinoma of the Head and Neck
Status: Recruiting, Estimated PCD: 2025-02-28
Product
Tirelizumab
Clinical trial
A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Status: Completed, Estimated PCD: 2023-03-15
Product
nimotuzumab
Clinical trial
A Phase II Study of Sodium Thiosulfate (STS) for Prevention of Ototoxicity in Patients With Locally Advanced Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Concurrent Chemoradiation With Cisplatin
Status: Completed, Estimated PCD: 2023-05-31
Clinical trial
Pilot Study of INCB081776 Together With Palliative Radiation and Anti-PD-1 Checkpoint Blockade With Pembrolizumab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Recruiting, Estimated PCD: 2026-08-01
Product
INCB081776
Clinical trial
A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-T in the Treatment of CD70-positive Refractory or Relapsed Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-04-21
Product
CHT101
Clinical trial
Phase I Trial of Sonidegib and Pembrolizumab in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Sonidegib
Clinical trial
A Phase II Study of Reirradiation With NBTXR3 in Patients With Inoperable Locoregional Recurrent Head and Neck Squamous Cell Carcinoma
Status: Withdrawn, Estimated PCD: 2022-11-21
Clinical trial
Non-invasive, Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy
Status: Recruiting, Estimated PCD: 2026-11-30
Product
18F-fluoromisonidazole
Clinical trial
A Single-Center, Single-Arm Exploratory Clinical Trial of Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced Head and Neck Squamous Cell Carcinoma
Status: Not yet recruiting, Estimated PCD: 2025-12-20
Product
3cycles
Product
AB598
Clinical trial
A Phase II Trial of a Protease Inhibitor, Nelfinavir (NFV), Given With Definitive, Concurrent Chemoradiotherapy (CTRT) in Patients With Locally-Advanced, Human Papilloma Virus (HPV) Negative, Squamous Cell Carcinoma of the Head and Neck
Status: Completed, Estimated PCD: 2021-05-01
Product
Nelfinavir
Clinical trial
A Randomized Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence
Status: Terminated, Estimated PCD: 2015-12-13
Drug
afatinib
Clinical trial
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff
Status: Recruiting, Estimated PCD: 2025-09-30
Drug
Spartalizumab
Clinical trial
Randomized Phase II Study of Immune Stimulation With Pembrolizumab and Radiotherapy in Second Line Therapy of Metastatic Head and Neck Squamous Cell Carcinoma (IMPORTANCE, Keynote-717, EudraCT NUMBER: 2017-002122-20 )
Status: Recruiting, Estimated PCD: 2024-01-01
Product
A (Pembrolizumab+RT)
Clinical trial
A Phase 1/2a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Status: Recruiting, Estimated PCD: 2025-04-01
Product
IMT-009
Product
Fruquintinib
Clinical trial
Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered Prior to Surgical Resection in Patients With Head and Neck Squamous Cell Carcinoma or Melanoma
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Product
MEDI0562
Clinical trial
A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Status: Completed, Estimated PCD: 2022-03-29
Clinical trial
Durvalumab (MEDI4736), Tremelimumab and Palliative Hypofractionated Image Guided Radiation Therapy (HIGRT) in Patients With Recurrent/Metastatic Squamous Cell Carcinomas of the Head and Neck Previously Treated With Immune Checkpoint Inhibitors
Status: Terminated, Estimated PCD: 2021-12-16
Clinical trial
Immune Checkpoint Inhibitors and Carbon iON Radiotherapy In Solid Cancers With Stable Disease
Status: Recruiting, Estimated PCD: 2025-08-01
Product
Immunotherapy (Pembrolizumab)
Clinical trial
Application of Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma: Phase II Clinical Study
Status: Recruiting, Estimated PCD: 2025-01-30
Drug
Pirfenidone
Clinical trial
A Phase II Study of PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma
Status: Withdrawn, Estimated PCD: 2023-05-12
Clinical trial
Randomized Phase II Trial Comparing Chemotherapy Combined With Stereotactic Radiotherapy and Stereotactic Radiotherapy Alone, for Treatment of Oligometastases in Squamous Cell Cancers of the Upper Aerodigestive Tract
Status: Active (not recruiting), Estimated PCD: 2026-07-01
Clinical trial
Safety and Efficacy Evaluation of Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (Non NPC): A Phase I Trial
Status: Completed, Estimated PCD: 2022-12-30
Clinical trial
Phase III Trial of Laryngeal Preservation Comparing Induction Chemotherapy With Cisplatin, 5-fluorouracil and Docetaxel (TPF) Followed by Radiotherapy and Concomitant Administration of Radiotherapy With Cisplatin
Status: Active (not recruiting), Estimated PCD: 2028-10-01
Clinical trial
Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer
Status: Recruiting, Estimated PCD: 2028-11-30
Clinical trial
Prospective, Single-arm, Phase II Clinical Study of Tirellizumab Combined With Carboplatin and Paclitaxel Polymer Micelles Neoadjuvant Therapy for cN+ Head and Neck Squamous Cell Carcinoma
Status: Not yet recruiting, Estimated PCD: 2026-12-30
Product
Polymeric Micellar Paclitaxel
Clinical trial
The Trifecta Study: Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
Status: Terminated, Estimated PCD: 2022-07-31
Product
Epacadostat
Product
CORVax
Product
Tavokinogene telseplasmid
Clinical trial
Induction Therapy With Nab-paclitaxel, Cisplatin and Pembrolizumab in Untreated Locally Advanced Head and Neck Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2025-01-01
Product
Nab-paclitaxel, cisplatin and Pembrolizumab
Product
Radical Concurrent Chemoradiotherapy
Clinical trial
A Window of Opportunity Study of Taxanes in Head and Neck Cancer
Status: Recruiting, Estimated PCD: 2026-04-01
Product
PEOX-based Polymer Encapsulated Paclitaxel
Clinical trial
Randomized Phase II Trial Contrasting Weekly Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Drug
cetuximab
Clinical trial
UCDCC#272: A Phase I/II Study of Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Standard-of-Care PD-1/PD-L1 Checkpoint Blockade
Status: Recruiting, Estimated PCD: 2023-12-01
Drug
interleukin-2
Clinical trial
Phase II Randomized Trial of Radiotherapy With Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients With Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN)
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
An Open-label, Non-randomized, Multi-arm, Phase II Trial to Evaluate the Efficacy of Pembrolizumab Combined With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Active (not recruiting), Estimated PCD: 2023-11-19
Clinical trial
Phase II Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma
Status: Not yet recruiting, Estimated PCD: 2024-12-01
Product
89Zr-panitumumab
Clinical trial
A Phase 2 Study of Ipatasertib in Combination With Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Status: Recruiting, Estimated PCD: 2025-06-30
Product
Ipatasertib
Clinical trial
Efficacy and Safety of Trilaciclib in Myeloprotection During Chemotherapy for Advanced/Recurrent Malignant Solid Tumors - A Phase II Study
Status: Not yet recruiting, Estimated PCD: 2025-09-30
Product
Trilaciclib
Clinical trial
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
Status: Completed, Estimated PCD: 2018-06-05
Clinical trial
Neoadjuvant Immunotherapy in Combination With Chemotherapy in Resectable Head and Neck Cancer：A Randomized, Phase II Study
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Product
Ivonescimab
Product
Cadonilimab
Clinical trial
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-05-01
Product
LY4052031
Abstract
https://www.abstractsonline.com/pp8/#!/10517/presentation/20183
Product
Subasumstat
Abstract
https://www.abstractsonline.com/pp8/#!/10828/presentation/10484
Clinical trial
A Prospective, Randomised Controlled, Phase II Clinical Study of Tirilizumab in Combination With Albumin-bound Paclitaxel With Cisplatin for Neoadjuvant and Adjuvant Treatment of Locally Advanced Resectable Oral Squamous Cell Carcinoma
Status: Recruiting, Estimated PCD: 2025-06-19
Product
Tirilizumab